Senior Writer, National Biotech Columnist
Adam Feuerstein is a Senior Writer and National Biotech Columnist. He covers a range of topics within medicine and healthcare, including the FDA, biotech innovations, and the implications of AI and machine learning in the healthcare system. Adam's insights and analyses have been featured in prominent publications such as the Boston Globe Technology, STAT, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Adam Feuerstein's coverage primarily revolves around the healthcare and pharmaceutical industry, with a strong emphasis on providing data-driven insights and expert commentary. He frequently references press releases and cites data to support his reporting.
To effectively reach out to Adam, consider offering access to exclusive data or research findings related to biotech, healthcare, pharmaceuticals, drug development, or FDA approval processes. Additionally, experts who can provide insightful analysis of industry trends or specific events will likely capture his attention.
As Adam's geographic focus is not specified but he covers global pharmaceutical and biotech industries extensively; therefore relevant information from any part of the world would be valuable for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Allison DeAngelis, Elaine Chen, Adam Feuerstein
Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.
By: Adam Feuerstein
In pre-JPM interview, Viehbacher says rare disease, immunology, and neurology are of interest
By: Adam Feuerstein
This is an excerpt from STAT , the health and medicine news site that's a partner to the Globe. For a full version of this story and related coverage, visit STAT
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
By: Jason Mast, Adam Feuerstein
By: Elaine Chen, Adam Feuerstein, Allison DeAngelis
What to watch for when Akero Therapeutics reports MASH-cirrhosis study results next month.
(833) 317-6278 
